Silence Therapeutics plc
SLN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001479615
No open-market purchases or sales by Silence Therapeutics plc insiders were filed in the last 90 days; 72 institutions reported holding it in 13F filings for Q2 2026, worth $236.2M in total; no superinvestor holds it.
Other share classesSLNCF
Q1 2022 vs. Q4 2021
How the institutions holding Silence Therapeutics plc changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 22 | 26 | +4 |
| Shares | 10.3M | 12.2M | +1.84M (+17.8%) |
| Value | $246.6M | $218.3M | −$28.4M (−11.5%) |
New holders (7)
Institutions that held Silence Therapeutics plc at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Lombard Odier Asset Management (Europe) Ltd | 1,561,551 | $29.7M | 1.14% |
| Frazier Life Sciences Management, L.P. | 881,173 | $16.7M | 1.43% |
| Altium Capital Management LP | 109,000 | $2.07M | 0.72% |
| Legal & General Group Plc | 14,973 | $288.0K | 0.00% |
| Deutsche Bank AG | 3,953 | $75.0K | 0.00% |
| Bank of America Corp | 770 | $15.0K | 0.00% |
| Tower Research Capital LLC (TRC) | 117 | $2.00K | 0.00% |
Sold out (3)
Institutions that held Silence Therapeutics plc at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Frazier Management LLC | 886,173 | $21.2M |
| JPMorgan Chase & Co | 6,730 | $157.0K |
| Cubist Systematic Strategies, LLC | 184 | $4.00K |